Kangmei Pharmaceutical Co., Ltd.

600518

CNE0000017M1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-29 EDT			5-day change	1st Jan Change
1.86 ^CNY	+0.54%		-3.12%	0.00%

04-30	Kangmei Pharmaceutical Logs Profit in Q1	MT
04-29	Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Kangmei Pharmaceutical Co., Ltd. Elects Zhang Hong as Independent Director; Plans to Invest RMB 3 Billion in Constructing China - Asean Kangmei Yulin Herbs Trading Center and Modern Logistics and Warehousing Projects

April 02, 2014 at 11:00 pm

Kangmei Pharmaceutical Co., Ltd. at the shareholders' meeting held on April 2, 2014 approved the proposal of electing Zhang Hong Independent Director of 6th directorate.

The company also approved the proposal of planning to invest RMB 3 billion in constructing China - ASEAN Kangmei Yulin Herbs (Spices) Trading Center and Modern Logistics and Warehousing Projects.

Latest news about Kangmei Pharmaceutical Co., Ltd.

Kangmei Pharmaceutical Logs Profit in Q1	04-30	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4%	04-14	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-12	CI
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit	03-26	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
China’s Securities Regulator Fines 37 Brokerages Since H1 2019	22-07-19	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Former Kangmei Chairman Loses Appeal Against 12-Year Sentence	22-01-11	MT
Kangmei Pharmaceutical Co., Ltd. announced that it has received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd.	21-12-14	CI
Kangmei Pharmaceutical Co., Ltd. announced that it expects to receive CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd.	21-12-13	CI
Kangmei Fraud Case Decision Triggers Exodus of Independent Directors From Listed Firms	21-11-21	MT
Kangmei to Get $1 Billion Government-Led Bailout	21-11-02	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-26	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-27	CI
Kangmei Pharmaceutical Co., Ltd. Appoints Zhou Yunfeng as Secretary to Directorate	21-02-18	CI
Market Chatter: GF Securities to Rejig Banking Operations After Client's Nearly $13 Billion Fraud Scandal	20-11-11	MT
Kangmei Pharmaceutical : Prices of China's Traditional Medicinal Materials Rise Tuesday	20-11-03	MT

Chart Kangmei Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Kangmei Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products intended primarily for treating hypertension and colds. The group offers Chinese medications (ginseng, salvia, codonopsis, etc.) and chemical medications (clarithromycin, doxazosin mesylate, paracetamol, etc.). All sales are earned in China.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KANGMEI PHARMACEUTICAL CO., LTD.	0.00%	3.54B
ELI LILLY AND COMPANY	+39.82%	731B
NOVO NORDISK A/S	+31.34%	586B
JOHNSON & JOHNSON	-7.31%	348B
MERCK & CO., INC.	+14.23%	319B
ABBVIE INC.	+0.86%	273B
ASTRAZENECA PLC	+13.47%	235B
ROCHE HOLDING AG	-6.63%	203B
NOVARTIS AG	+7.49%	202B
AMGEN INC.	+4.51%	159B

Other Pharmaceuticals